The current direction of modern pharmacology is the development of therapeutic approaches for correcting the course of comorbid (combined) pathology, the growth of which has been observed lately. This problem has been devoted to a complex experimental and clinical study aimed to improve the periodontal care in people with urolithiasis through the development of pathogenetic pharmacological therapy.
The purpose of this experimental study is to learn parodonto protective effects of simultaneous use of thiotriazoline and urolesan taking into account the background of urolithiasis. The purpose of this goal has determined the task of processing pathogenetic pharmacotherapy of periodontal diseases in urolithiasis: a complex experiment has been carried out for modeling of the comorbid state of urolithiasis / periodontitis, and hence, the definition of rational combinations of medicines according to the criteria of influence on indicators of lithogenesis and inflammatory processes.
The design of the experiment has involved modeling of comorbid pathology – peroxide periodontitis on the background of ethylene glycol nephrolithiasis, which has been carried out on white rats. The pathogenetic correspondence of model coomorphic pathology has been verified in the experiment on statistically reliable data: digital values of kidney function parameters, levels of ion promoters of lithogenesis, biochemical parameters of lipid peroxidation, creatinine, obtained on the material of biological environments of experimental animals (urine, blood, jaw tissue homogenates).
According to the dynamics of the levels of inorganic metabolites, the simultaneous reduction of uric calcium ion concentration with a decrease in the urinary concentration of oxalate ions in animals received by using the thiotriazoline + urolesan complex is an important effect which has shown that experimental therapy has greatly inhibited the synthesis level in the nephrons of crystalline oxalate calcium thereby, preventing the saturation of urine with them. Changes in these indices have served as criteria for the efficacy of the combination of thiotriazoline and urolesan in this experimental study.
The data have showed the antioxidant effect of experimental pharmacotherapy both on the levels of MDA and catalase, and on their ratios, expressed by the index values of API. So, the results of the change in the activity of elastase and acid phosphatase have indicated an expressive anti-inflammatory character of the thiotriazoline + urolesan complex. The obtained results indicate the efficacy of the combination of thiotriazoline / urolesan as a means of pharmaco-correction of inflammatory periodontal diseases on the background of urolithiasis.
To sum up, it can be argued that the studies have showed the normalizing effect of experimental therapies on the functional state of kidney and levels of urine metabolites in animals with a model pathology (experimental urolithiasis and periodontitis) with reliable advantages of the combination of thiotriazoline + urolesan, and the biochemical parameters of the lipid peroxidation system have showed the antioxidant effect on the studied drug combinations. Thus, the use of the thiotriazoline + urolesan complex has caused nephroprotective effects and periodontal projection effects in experimental comorbid pathology, which substantiates the expediency of their combined use in order to obtain an adequate therapeutic effect in the treatment of inflammatory conditions of periodontal disease in the context of urolithiasis and conducting clinical trials in this direction.
Full text: PDF (Ukr) 1.84M